TrialRespiratory research2026

Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA).

Tania Hugo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.